Pubblicazioni

2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma

2023 - ANNALS OF ONCOLOGY
Occhipinti, M.; Brambilla, M.; Ambrosini, P.; Pannone, A.; Zanella, C.; Leone, A. G.; Leporati, R.; Fotia, G.; Di Mauro, R.; Ianza, A.; Manglaviti, S.; Beninato, T.; Mazzeo, L.; Proto, C.; Prelaj, A.; Percio, S.; De Braud, F. G. M.; Lo Russo, G.; Generali, D.; Ganzinelli, M.

1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib

2023 - ANNALS OF ONCOLOGY
Brambilla, M.; Lorenzini, D.; Occhipinti, M.; Manglaviti, S.; Beninato, T.; Mazzeo, L.; Agnelli, L.; Leporati, R.; Zanella, C.; Leone, A. G.; Fotia, G.; Prelaj, A.; Lo Russo, G.; Grande, I.; Tamborini, E.; Perrone, F.; Ganzinelli, M.; Pruneri, G.; De Braud, F. G. M.; Proto, C.

178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients

2023 - ANNALS OF ONCOLOGY
Provenzano, L.; Favali, M.; Mazzeo, L.; Spagnoletti, A.; Giani, C.; Calareso, G.; Ruggirello, M.; Greco, F. G.; Vigorito, R.; Occhipinti, M.; Brambilla, M.; Manglaviti, S.; Proto, C.; Lo Russo, G.; Trovò, F.; De Braud, F. G. M.; Ganzinelli, M.; Pedrocchi, A.; Miskovic, V.; Prelaj, A.

P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study

2023 - ANNALS OF ONCOLOGY
Signorelli, C.; Calegari, M.; Basso, M.; Anghelone, A.; Lucchetti, J.; Minelli, A.; Angotti, L.; Zurlo, I.; Schirripa, M.; Chilelli, M.; Morelli, C.; Dell’Aquila, E.; Cosimati, A.; Gemma, D.; Ribelli, M.; Corsi, D.; Arrivi, G.; Zoratto, F.; Morandi, M.; Santamaria, F.; Saltarelli, R.; Ruggeri, E.

P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis

2023 - ANNALS OF ONCOLOGY
Trovato, G.; Valente, G.; Calegari, M.; Dell’Aquila, E.; Anghelone, A.; Lucchetti, J.; Schietroma, F.; Zurlo, I.; Signorelli, C.; Morelli, C.; Zoratto, F.; Caira, G.; Spring, A.; Saltarelli, R.; Cosimati, A.; Schirripa, M.; Santamaria, F.; Angotti, L.; Salvatore, L.; Pozzo, C.; Basso, M.; Tortora, G.

P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis

2023 - ANNALS OF ONCOLOGY
Caira, G.; Calegari, M.; Anghelone, A.; Lucchetti, J.; Dell’Aquila, E.; Signorelli, C.; Spring, A.; Saltarelli, R.; Cosimati, A.; Zurlo, I.; Angotti, L.; Schietroma, F.; Pozzo, C.; Chiofalo, L.; Santamaria, F.; Morelli, C.; Zoratto, F.; Schirripa, M.; Salvatore, L.; Basso, M.; Tortora, G.

127P {RAS}, {RAF} and {NF}1 oncogenic mutations in {KRAS}-mutated lung adenocarcinoma

2022 - ANNALS OF ONCOLOGY
Marinelli, D.; Pisegna, S.; Chiavassa, A.; Bengala, E.; Capasso, C.; Sabatini, A.; Ciurluini, F.; Artemi, A.; Torchia, A.; Gallina, F. T.; Botticelli, A.; Gazzaniga, P.; Cortesi, E.; Gelibter, A. J.

56P The prognostic role of {KRAS} mutations in patients with early-stage lung adenocarcinoma after robotic lobectomy and systematic lymphadenectomy

2022 - ANNALS OF ONCOLOGY
Gallina, F. T.; Marinelli, D.; Forcella, D.; Taj(`(e)), R.; Ceddia, S.; Fusco, F.; Melis, E.; Buglioni, S.; Visca, P.; Cappuzzo, F.; Facciolo, F.

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma

2022 - ANNALS OF ONCOLOGY
Scalera, S; Ricciuti, B; Mazzotta, M; Calonaci, N; Alessi, Joao V; Cipriani, L; Bon, G; Messina, B; Lamberti, G; Di Federico, A; Pecci, F; Milite, S; Krasniqi, E; Barba, M; Vici, P; Vecchione, A; De Nicola, F; Ciuffreda, L; Goeman, F; Fanciulli, M; Buglioni, S; Pescarmona, E; Sharma, B; Felt, K D; Lindsay, J; Rodig, S J; De Maria, R; Caravagna, G; Cappuzzo, F; Ciliberto, G; Awad, M M; Maugeri-Saccà, M

Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients

2022 - ANNALS OF ONCOLOGY
Prelaj, A; Bottiglieri, A; Provenzano, L; Spagnoletti, A; Mazzeo, L; Miskovic, V; Ganzinelli, M; Lo Russo, G; Ferrara, R; Proto, C; De Toma, A; Brambilla, M; Occhipinti, M; Manglaviti, S; Beninato, T; Rametta, A; Garassino, Mc; De Braud, Fgm; Trovo, F; Pedrocchi, A

KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC

2022 - ANNALS OF ONCOLOGY
Bottiglieri, A; Provenzano, L; Spagnoletti, A; Mazzeo, L; Ganzinelli, M; Lo Russo, G; Ferrara, R; Proto, C; De Toma, A; Brambilla, M; Occhipinti, M; Manglaviti, S; Beninato, T; Garassino, Mc; Filosa, J; Di Guida, G; De Braud, Fgm; Viscardi, G; Della Corte, Cm; Prelaj, A

Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations

2022 - ANNALS OF ONCOLOGY
Ferrara, R; Lo Russo, G; Ciniselli, Cm; Gregorio, S; Calareso, G; Bassani, B; Proto, C; Prelaj, A; De Toma, A; Occhipinti, M; Brambilla, M; Manglaviti, S; Mazzeo, L; Beninato, T; Ganzinelli, M; De Braud, Fgm; Garassino, Mc; Colombo, Mp; Verderio, P; Sangaletti, S

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations

2022 - ANNALS OF ONCOLOGY
Beninato, T; Brambilla, M; Pircher, Cc; Mazzeo, L; Rametta, A; Manglaviti, S; De Toma, A; Galli, G; Prelaj, A; Ferrara, R; Proto, C; Lo Russo, G; Ganzinelli, M; Di Mauro, R; Di Nucci, A; Garassino, Mc; Marchetti, P; De Braud, Fgm; Occhipinti, M

DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients

2022 - ANNALS OF ONCOLOGY
Filetti, M; Occhipinti, M; Cirillo, A; Scirocchi, F; Ugolini, A; Petti, M; Giusti, R; Lombardi, P; Botticelli, A; Lo Russo, G; De Braud, Fgm; Marchetti, P; Nuti, M; Ferretti, E; Rughetti, A; Farina, L

133P ARID1A-mutated cancers: New prospectives for treatment of a subgroup of gynecological cancer

2022 - ANNALS OF ONCOLOGY
Falcone, R.; Filetti, M.; Lombardi, P.; Altamura, V.; Scambia, G.; Daniele, G.

1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis

2022 - ANNALS OF ONCOLOGY
Filetti, M.; Lombardi, P.; Falcone, R.; Giannarelli, D.; Carcagnì, A.; Giusti, R.; Scambia, G.; Daniele, G.

398P Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment

2022 - ANNALS OF ONCOLOGY
Signorelli, C.; Schirripa, M.; Chilelli, M. G.; Calegari, M. A.; Basso, M.; Anghelone, A.; Lucchetti, J.; Minelli, A.; Angotti, L.; Morelli, C.; Dell'Aquila, E.; Cosimati, A.; Gemma, D.; Ribelli, M.; Corsi, D. C.; Arrivi, G.; Zoratto, F.; Morandi, M. G.; Santamaria, F.; Saltarelli, R.; Ruggeri, E. M.

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer

2022 - ANNALS OF ONCOLOGY
Filetti, S; Durante, C; Hartl, D M; Leboulleux, S; Locati, L D; Newbold, K; Papotti, M G; Berruti, A

New Prognostic Frontiers for Lung Neuroendocrine Tumors

2022 - ANNALS OF ONCOLOGY
Salvia, Al; Persano, I; Siciliani, A; Verrico, M; Bassi, M; Modica, R; Audisio, A; Zanata, I; Marinucci, Bt; Trevisi, E; Puliani, G; Rinzivillo, M; Parlagreco, E; Faggiano, A

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

2022 - ANNALS OF ONCOLOGY
Di Maio, M.; Basch, E.; Denis, F.; Fallowfield, L. J.; Ganz, P. A.; Howell, D.; Kowalski, C.; Perrone, F.; Stover, A. M.; Sundaresan, P.; Warrington, L.; Zhang, L.; Apostolidis, K.; Freeman-Daily, J.; Ripamonti, C. I.; Santini, D.

1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy

2021 - ANNALS OF ONCOLOGY
Zattarin, E.; Manglaviti, S.; Galli, E.; Apollonio, G.; Beninato, T.; Mazzeo, L.; Massa, G.; Bottiglieri, A.; Ganzinelli, M.; Proto, C.; Ferrara, R.; Prelaj, A.; Galli, G.; De Toma, A.; Brambilla, M.; Occhipinti, M.; Garassino, M. C. C.; De Braud, F. G. M.; Lo Russo, G.

1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation

2021 - ANNALS OF ONCOLOGY
Prelaj, A.; Bottiglieri, A.; Galli, E.; Lo Russo, G.; Ferrara, R.; Galli, G.; De Toma, A.; Brambilla, M.; Occhipinti, M.; Manglaviti, S.; Beninato, T.; Zattarin, E.; Apollonio, G.; Ganzinelli, M.; Gallucci, R.; Di Mauro, R. M.; de Braud, F.; Torri, V.; Garassino, M. C. C.; Proto, C.

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines

2021 - ANNALS OF ONCOLOGY
Lacouture, Me; Sibaud, V; Gerber, Pa; van den Hurk, C; Fernandez-Penas, P; Santini, D; Jahn, F; Jordan, K

3MO Oncogenic non-G12C {KRAS} mutations in {KRAS} G12C mutated lung adenocarcinomas in {TRACERx} and {GENIE}: A reservoir for intrinsic resistance to {KRAS} G12C inhibitors

2021 - ANNALS OF ONCOLOGY
Marinelli, D.; Pisegna, S.; Giammaruco, M.; Chesi, P.; Mammone, G.; Ceddia, S.; Gazzaniga, P.; Cortesi, E.; Gelibter, A. J.

Inflammation reduces the effect of nutritional therapy on clinical outcomes in cancer patients.

2021 - ANNALS OF ONCOLOGY
Bargetzi, L; Bargetzi, M; Laviano, A; Stanga, Z; Schuetz, P.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma